Social media endorsements on behalf of Big Pharma is big business. More than 9 in 10 physicians who posted their support for a drug or medical device on X were paid by drugmakers, according to a recent study published in JAMA. These payments totaled $2.46 billion in 2022.

"The conflict of interest may not be apparent to the general social media audience," researchers said. "These payments can represent scientific collaboration but may involve marketing efforts without scientific benefits, raising concerns regarding their influence on clinical decision-making."

Researchers used Open Payments, a website run by the Centers for Medicare and Medicaid Services, to verify payment data. Open Payments is a comprehensive database that allows the public to see how much money doctors receive from pharmaceutical companies, whether for research, speaking fees, consulting or other forms of compensation. Among the key findings:

  • Twenty-six of the 28 physicians included in the study received payments from pharmaceutical companies for a variety of reasons, most often noted as food and beverages, speaking or consulting fees.
  • The average payment to doctors from drugmakers was around $27,400.
  • Most of Big Pharma's payments to doctors went toward "speaking," with some $377,000 paid to 18 physicians for speaking activities.
  • Researchers also pinpointed 24 times in which physicians received payments that were linked to them mentioning a specific drug or medical device on X.
  • Half of the doctors who endorsed drugs on X had no research publications related to the products, and almost half of the physicians did not disclose that they were being paid by the drugmakers.
  • The companies that paid physicians surveyed in the study included Pfizer, GSK, Eisai, AstraZeneca, Novartis, Exelixis and Boston Scientific.

Related: UnitedHealth's PBM, Optum RX, launches a more 'transparent' drug pricing model

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.